May 27, 2016
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) has approved lenvatinib (Lenvima, Eisai), in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma who were previously treated with an anti-angiogenic ther"...



How Supplied


Neumega (oprelvekin) is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle. Neumega (oprelvekin) is not indicated following myeloablative chemotherapy (see WARNINGS, Increased Toxicity Following Myeloablative Therapy). The safety and effectiveness of Neumega (oprelvekin) have not been established in pediatric patients.


The recommended dose of Neumega (oprelvekin) in adults without severe renal impairment is 50 µg/kg given once daily. Neumega (oprelvekin) should be administered subcutaneously as a single injection in either the abdomen, thigh, or hip (or upper arm if not self-injecting). A safe and effective dose has not been established in children (see PRECAUTIONS, Pediatric Use).

The recommended dose of Neumega (oprelvekin) in adults with severe renal impairment (creatinine clearance < 30 mL/min) is 25 µg/kg. An estimate of the patient's creatinine clearance (CLcr) in mL/min is required. CLcr in mL/min may be estimated from a spot serum creatinine (mg/dL) determination using the following formula:

CLcr≈ [140 - age (years)] x weight (kg) {x 0.85 for female patients}
72 x serum creatinine (mg/dL)

Dosing should be initiated six to 24 hours after the completion of chemotherapy. Platelet counts should be monitored periodically to assess the optimal duration of therapy. Dosing should be continued until the post-nadir platelet count is ≥ 50,000/µL. In controlled clinical trials, doses were administered in courses of 10 to 21 days. Dosing beyond 21 days per treatment course is not recommended.

Treatment with Neumega (oprelvekin) should be discontinued at least two days before starting the next planned cycle of chemotherapy.

Preparation of Neumega (oprelvekin)

  1. Neumega (oprelvekin) is a sterile, white, preservative-free, lyophilized powder for subcutaneous injection upon reconstitution. Reconstitute the Neumega (oprelvekin) 5 mg vial using the 1.0 mL of Sterile Water for Injection, USP (without preservative) contained in the pre-filled syringe included in the kit. The reconstituted Neumega (oprelvekin) solution is clear, colorless, isotonic, with a pH of 7.0, and contains 5 mg/mL of Neumega (oprelvekin) . Any unused portion of the reconstituted Neumega (oprelvekin) solution should be discarded.
  2. During reconstitution, the Sterile Water for Injection, USP should be directed at the side of the vial and the contents gently swirled. Excessive or vigorous agitation should be avoided.
  3. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter is present or the solution is discolored, the vial should not be used.
  4. Administer Neumega (oprelvekin) within 3 hours following reconstitution. Reconstituted Neumega (oprelvekin) may be refrigerated [2°C to 8°C (36°F to 46°F)] or maintained at room temperature [up to 25°C (77°F)]. Do not freeze or shake the reconstituted solution.


Neumega (oprelvekin) is supplied as a sterile, white, preservative-free, lyophilized powder in vials containing 5 mg oprelvekin. Neumega (oprelvekin) is available in boxes containing one single-dose Neumega (oprelvekin) vial and one pre-filled syringe containing 1 mL Sterile Water for Injection, USP. - NDC 58394-004-08


The kit containing the vial of lyophilized Neumega (oprelvekin) and pre-filled diluent syringe should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect Neumega (oprelvekin) powder from light. Do not freeze.

This product's label may have been updated. For current package insert and further product information, please visit or call our medical communications department toll-free at 1-800-934-5556. Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101. Rev 03/08. FDA Rev date: 9/13/2006

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 10/21/2008

How Supplied

Neumega - User Reviews

Neumega User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Neumega sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.

Health Resources
Related Supplements
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations